Why is Novo Nordisk stock sliding today?

Novo Nordisk fell 2.8% to DKK 278.2 after Morgan Stanley downgraded the stock to Underweight, citing slowing medium-term growth, market-share losses and semaglutide patent-cliff risk. Morgan Stanley expects only 2-3% revenue and EBIT growth in 2027 and 4% CAGR in both through 2030, versus 4% revenue and 7% EBIT CAGR for European pharma. Semaglutide is projected to account for 75% of 2026 sales and 59% of 2031 sales as patent expiries begin, outweighing HSBC's modest DKK 20 target increase to DKK 320 and Novo's DKK 15B buyback program.

Analysis

The investable issue is not the next prescription-data point but a potential reset in NVO’s terminal multiple: a business priced for durable obesity-market leadership cannot sustain a premium if growth decelerates toward large-pharma levels while its revenue concentration remains unusually high. Incremental share loss also has asymmetric operating leverage because NVO’s manufacturing expansion and commercial investment were built for materially higher volume; lower utilization would pressure gross margin and make buybacks a weaker offset to estimate cuts. LLY is the clearest share-take beneficiary, though its own valuation leaves it exposed if the obesity category’s net pricing or persistence economics disappoint.

Near term, this is likely an estimate-revision and multiple-compression story rather than a patent-expiry trade. The relevant 1-3 month catalysts are obesity prescription and new-start data, formulary decisions for the 2026 plan year, supply availability, and any revision to NVO’s volume, realized-price, or capacity-utilization outlook. Over 6-18 months, trial readouts and launch timing for next-generation oral/incretin therapies determine whether NVO can defend the franchise before mature-product concerns become valuation-relevant.

The contrarian case is that pessimism is being pulled forward: patent cliffs more than five years away should have limited standalone impact on near-term DCF value if NVO refreshes the portfolio and continues to convert untreated patients. Before treating the downgrade as fundamental confirmation, verify the cited physician survey, competitor-product references, and jurisdiction-specific exclusivity dates; the source is AI-assisted and these inputs are not independently validated here. A durable reversal would require evidence of stabilizing share plus maintained margin guidance, not simply a short-covering bounce.

Key Decisions for Investors

• Maintain a 1-3 month NVO underweight or initiate a modest short only after confirming current prescription-share data and patent assumptions; target additional downside from consensus EPS/EBIT revisions rather than the single rating action. Cover if NVO reaffirms growth and margin guidance while sequential obesity share stabilizes for two reporting periods.
• Express relative share-transfer exposure via long LLY / short NVO, sized beta-neutral, over the next 3-6 months. The pair reduces broad GLP-1 category risk; key risk is LLY’s premium multiple compressing faster than NVO, so stop the trade if LLY guidance weakens or the pair fails to widen after the next prescription-data cycle.
• Do not treat the buyback as a standalone long catalyst. Monitor whether repurchases are funded from excess free cash flow after capacity spending; a rising net-debt trajectory or lower capital-return capacity would remove an important downside buffer for NVO.
• Set an event watch for NVO’s next earnings release: downgrade the short thesis if management shows stable realized pricing, improved supply conversion, and no reduction in medium-term operating-margin targets; add only if guidance cuts are tied to demand/share rather than temporary manufacturing execution.